SUPPRESSION OF AUTOIMMUNE RESPONSES AND INFLAMMATORY EVENTS BY LEFLUNOMIDE IN AN ANIMAL-MODEL FOR RHEUMATOID-ARTHRITIS

被引：8

作者：

GLANT, TT

MIKECZ, K

BRENNAN, F

NEGROIU, G

BARTLETT, RR

机构：

[1] RUSH MED UNIV,RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT ORTHOPED SURG,CHICAGO,IL 60612

[2] HOECHST AG,PHARMAKOL FORSCH,D-65174 WIESBADEN,GERMANY

来源：

AGENTS AND ACTIONS | 1994年 / 41卷

关键词：

D O I：

10.1007/BF01987665

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

The effect of leflunomide (HWA 486) was tested in proteoglycan-induced arthritis in an autoimmune animal model showing many similarities to human rheumatoid arthritis and ankylosing spondylitis. The development of the disease in genetically susceptible BALB/c mice is dependent upon the expression of both cell-mediated and humoral immunity to host mouse cartilage proteoglycan. Arthritic and control (non-arthritic) animals were treated with 35 mg leflunomide/kg body weight/day for 12 weeks to suppress inflammatory events and antibody titers. Leflunomide suppressed acute inflammatory events, protected animals from new inflammatory episodes and acute exacerbations, slightly reduced the stiffness in joints and blocked the degradation of cartilage. The suppressive effect of leflunomide in proteoglycan-induced arthritis is due primarily to the suppression of autoantibody formation.

引用

页码：C267 / C270

页数：4

共 19 条

[1]

Bartlett R R, 1988, Scand J Rheumatol Suppl, V75, P290

[2] IMMUNOPHARMACOLOGICAL PROFILE OF A NOVEL ISOXAZOL DERIVATIVE, HWA-486, WITH POTENTIAL ANTIRHEUMATIC ACTIVITY .1. DISEASE MODIFYING ACTION ON ADJUVANT ARTHRITIS OF THE RAT [J].

BARTLETT, RR ;

SCHLEYERBACH, R .

INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1985, 7 (01) :7-+

[3]

BARTLETT RR, 1989, THERAPEUTIC APPROACHES TO INFLAMMATORY DISEASES, P215

[4] LEFLUNOMIDE (HWA-486), A NOVEL IMMUNOMODULATING COMPOUND FOR THE TREATMENT OF AUTOIMMUNE DISORDERS AND REACTIONS LEADING TO TRANSPLANTATION REJECTION [J].

BARTLETT, RR ;

DIMITRIJEVIC, M ;

MATTAR, T ;

ZIELINSKI, T ;

GERMANN, T ;

RUDE, E ;

THOENES, GH ;

KUCHLE, CCA ;

SCHORLEMMER, HU ;

BREMER, E ;

FINNEGAN, A ;

SCHLEYERBACH, R .

AGENTS AND ACTIONS, 1991, 32 (1-2) :10-21

[5] IMMUNOPHARMACOLOGICAL PROFILE OF HWA-486, A NOVEL ISOXAZOL DERIVATIVE .2. INVIVO IMMUNOMODULATING EFFECTS DIFFER FROM THOSE OF CYCLOPHOSPHAMIDE, PREDNISOLONE, OR CYCLOSPORINE-A [J].

BARTLETT, RR .

INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1986, 8 (02) :199-204

[6]

BUZAS EI, 1993, CLIN EXP IMMUNOL, V94, P252

[7]

CHONG ASF, 1993, TRANSPLANT P, V25, P747

[8] LEFLUNOMIDE, A NOVEL IMMUNOSUPPRESSIVE AGENT - THE MECHANISM OF INHIBITION OF T-CELL PROLIFERATION [J].

CHONG, ASF ;

FINNEGAN, A ;

JIANG, XL ;

GEBEL, H ;

SANKARY, HN ;

FOSTER, P ;

WILLIAMS, JW .

TRANSPLANTATION, 1993, 55 (06) :1361-1366

[9] CARTILAGE PROTEOGLYCAN-INDUCED ARTHRITIS IN BALB/C MICE - ANTIBODIES THAT RECOGNIZE HUMAN AND MOUSE CARTILAGE PROTEOGLYCAN AND CAN CAUSE DEPLETION OF CARTILAGE PROTEOGLYCAN WITH LITTLE OR NO SYNOVITIS [J].

DAYER, E ;

MATHAI, L ;

GLANT, TT ;

MIKECZ, K ;

POOLE, AR .

ARTHRITIS AND RHEUMATISM, 1990, 33 (09) :1394-1405

[10]

Glant T. T., 1991, MONOCLONAL ANTIBODIE, P341

← 1 2 →